Cassava Sciences' controversial Alzheimer's drug fails in second late-stage study

Cassava Sciences (SAVA.O), opens new tab said on Tuesday its Alzheimer's drug simufilam, which has been at the center of regulatory scrutiny, failed in a second late-stage study, sending shares of the company down 20% in early trading.